These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 2130305)

  • 41. Elevated serum pepsinogens in chronic renal failure patients.
    Nakahama H; Tanaka Y; Shirai D; Nishihara F; Takamitsu Y; Nakanishi T; Sugita M
    Nephron; 1995; 70(2):211-6. PubMed ID: 7566306
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Albuminuria in acute and chronic renal failure.
    Ravnskov U
    Acta Med Scand; 1973; 1-2(1):59-64. PubMed ID: 4199389
    [No Abstract]   [Full Text] [Related]  

  • 43. PROLONGED PERITONEAL DIALYSIS FOR CHRONIC RENAL FAILURE.
    PALMER RA; QUINTON WE; GRAY JE
    Lancet; 1964 Mar; 1(7335):700-2. PubMed ID: 14107960
    [No Abstract]   [Full Text] [Related]  

  • 44. [Differences in mechanisms of alterations in thrombocyte and erythrocyte aggregation in renal failure].
    Potapova IV; Potapov VV
    Biull Eksp Biol Med; 1980 Mar; 89(3):263-5. PubMed ID: 7388129
    [No Abstract]   [Full Text] [Related]  

  • 45. [Electrolyte disorders in patients with chronic renal insufficiency].
    Glezer GA; Nikolaeva EN
    Ter Arkh; 1968 Jun; 40(6):81-4. PubMed ID: 5739217
    [No Abstract]   [Full Text] [Related]  

  • 46. [The characteristics of disorders in carbohydrate metabolism and insulin and C-peptide secretion in patients with chronic glomerulonephritis in developing chronic kidney failure].
    Trusov VV; Kazakova IA
    Ter Arkh; 1996; 68(6):21-4. PubMed ID: 8771677
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Plasmapheresis treatment of idiopathic rapidly progressive glomerulonephritis.
    Arrizabalaga P; Torras A; Montoliu J; Bergadá E; Botey A; Puig L; Darnell A; Revert L
    Int J Artif Organs; 1983 Jul; 6 Suppl 1():19-20. PubMed ID: 6642730
    [No Abstract]   [Full Text] [Related]  

  • 48. Serum concentration of IL-2, IL-6, TNF-alpha and their soluble receptors in children on maintenance hemodialysis.
    Zwolińska D; Medyńska A; Szprynger K; Szczepańska M
    Nephron; 2000 Dec; 86(4):441-6. PubMed ID: 11124592
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ochratoxin A in human serum samples collected in southern Italy from healthy individuals and individuals suffering from different kidney disorders.
    Breitholtz-Emanuelsson A; Minervini F; Hult K; Visconti A
    Nat Toxins; 1994; 2(6):366-70. PubMed ID: 7704450
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Kidney circulation in chronic parenchyma diseases and in kidney insufficiency].
    Buchali K; Zimmermann HB
    Z Urol Nephrol; 1977 May; 70(5):305-9. PubMed ID: 899309
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Association between plasma phosphorus and renal outcome: A prospective cohort of patients majorly with glomerulonephritis.
    Xu D; Lv J; Wang J; Zhang L; Zhang H
    Nephrology (Carlton); 2017 Jan; 22(1):43-48. PubMed ID: 26769231
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of progression of renal failure in children with hypoplastic-dysplastic kidneys and chronic glomerulonephritis.
    Chao SM; Saw AH; Yap HK; Tan SP; Murugasu B; Tay AH
    Singapore Med J; 1991 Oct; 32(5):304-6. PubMed ID: 1788570
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Metabolomic identification of potential phospholipid biomarkers for chronic glomerulonephritis by using high performance liquid chromatography-mass spectrometry.
    Jia L; Wang C; Zhao S; Lu X; Xu G
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Dec; 860(1):134-40. PubMed ID: 17996503
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [The crythrocyte system in terminal renal failure caused by chronic glomerulonephritis, treated by hemodialysis].
    Dobiecka-Wawrzecka B
    Wiad Lek; 1980 Jun; 33(11):849-54. PubMed ID: 7423987
    [No Abstract]   [Full Text] [Related]  

  • 55. [Thrombocyto- and coagulopathies in patients with diabetic glomerulosclerosis and chronic glomerulonephritis].
    Lapchyns'ka II; Bielyts'ka HO; Lezhen TI; Ishchenko VM; Fedorova NIe
    Lik Sprava; 1996; (3-4):74-7. PubMed ID: 9035889
    [No Abstract]   [Full Text] [Related]  

  • 56. [The mechanism of Na+--K+ pump dysfunction in the erythrocytes of patients with glomerulonephritis and kidney failure].
    Ponomarenko ED; Lazovskis IR; Pletneva TP; Maslova MN
    Ter Arkh; 1991; 63(5):105-9. PubMed ID: 1653466
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term outcomes for primary glomerulonephritis: New Zealand Glomerulonephritis Study.
    Chembo CL; Marshall MR; Williams LC; Walker RJ; Lynn KL; Irvine J; Pilmore HL
    Nephrology (Carlton); 2015 Dec; 20(12):899-907. PubMed ID: 26096749
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The blood pro- and antioxidant status in patients with chronic glomerulonephritis and disordered kidney function undergoing treatment with peroral sorbents].
    Tugusheva FA; Kulikova AI; Lukichev BG; Zubina IM
    Urol Nefrol (Mosk); 1994; (6):39-42. PubMed ID: 7892720
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Transcobalamin II. A specific marker of renal involvement in essential mixed cryoglobulinemia.
    Biosca M; Encabo G; Garcia-Bragado F; Mañe S; Ruibal A; Vilardell YM
    Nephron; 1987; 45(3):255-6. PubMed ID: 3574578
    [No Abstract]   [Full Text] [Related]  

  • 60. Interleukin-2 receptor as an immunodiagnostic tool to differentiate rejection from nephrotoxicity.
    Smith AY; Citterio F; Welsh M; Kerman RH; Kahan BD
    Transplant Proc; 1989 Feb; 21(1 Pt 2):1462-4. PubMed ID: 2652467
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.